<DOC>
	<DOCNO>NCT01270841</DOCNO>
	<brief_summary>The Purpose study determine effect Androxal morning testosterone reproductive status men secondary hypogonadism ( confirmed morning Testosterone le 250 ng/dL ) , compare change placebo , Testim ( topical testosterone ) . The effect Testim versus placebo reproductive status also examine . Study subject must currently use topical testosterone .</brief_summary>
	<brief_title>Normalization Morning Testosterone Levels Men With Secondary Hypogonadism</brief_title>
	<detailed_description>This study phase IIb , 4 arm study three month active dosing period . Three four treatment group randomize either Androxal placebo double-blind fashion , fourth treatment group receive open-label Testim . The dos Androxal blind portion study 12.5 mg 25 mg , capsule form .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>Healthy male age 21 65 year age All clinical laboratory test within normal range ( clinically significant deviation laboratory result require approval sponsor ) Previously concurrently diagnose secondary hypogonadism confirm morning testosterone &lt; 250ng/dL ( two assessment least 10 day apart ) Ability complete study compliance protocol Ability understand provide write informed consent Agreement use double barrier contraception fertile female partner Agreement provide semen sample clinic Use injectable , oral , topical , subcutaneous pelleted testosterone within 6 month prior study Use spironolactone , cimetidine , Clomid , 5Î±reductase inhibitor , hCG , androgen , estrogen , anabolic steroid , DHEA , herbal hormone product study Use Clomid past year Uncontrolled hypertension diabetes mellitus base Investigator 's assessment baseline . Subjects treat Type II diabetes exhibit glycemic control allow study A hematocrit &gt; 50 % hemoglobin &gt; 17 g/dL Clinically significant abnormal finding screen examination Use investigational drug product , participation drug medical device research study within 30 day prior receive study medication Known hypersensitivity Clomid Symptomatic cataract ( nuclear sclerosis cataract cortical cataract grade &gt; 2 base 04 scale trace posterior subcapsular cataract ) Any condition opinion investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part study Irreversibly infertile compromise fertility ( cryptorchism , Kallman Syndrome , primary hypogonadism , vasectomy , tumor pituitary ) Current history breast cancer Current history prostate cancer suspicion prostate disease unless rule prostate biopsy , PSA &gt; 3.6 Presence history hyperprolactinemia without tumor Chronic use medication use glucocorticoid Subjects cystic fibrosis ( mutation CFTR gene ) Subjects unable provide semen sample clinic Subject BMI &gt; 36 kg/m2</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>